IntelGenx drops plans to buy pharmaceutical consulting firm
Insight Weekly: PE firms shift strategies; bank earnings kick off; bankruptcies plummet
Insight Weekly: Stocks limp into 2023; GCC banks set for rebound; deep-sea mining faces pushback
Infographic: The Big Picture 2023 Sustainability Outlook
The Big Picture for 2023: Assessing Investment Trends and the Impact of Investor Activism
IntelGenx Technologies Corp. said March 27 that it is no longer looking to raise $10 million to fund the acquisition of a pharmaceutical consulting firm.
The company canceled its placement due to market conditions. The Canadian drug delivery company's acquisition of LaboVal Inc. was dependent on the financing.
